Drugs / RS-113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07553988 | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-21 | R-Pharm | Results Р-Фарм выводит на рынок новые препараты против онкологических заболеваний r-pharm.com ↗
По итогам шести месяцев терапии RS-113 подтвердил высокую эффективность, сопоставимую с таковой у абиратерона — стандарта терапии рака предстательной железы. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-21 | R-Pharm | Р-Фарм выводит на рынок новые препараты против онкологических заболеваний r-pharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS-113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07553988 ↗ |
| Route | Oral | “RS-113 is taken once daily (QD) orally” NCT07553988 ↗ |